Cart (0 Items)
Your cart is currently empty.
View ProductsStable Isotope Labelled Vedolizumab Biosimilar – Anti-ITGA4_ITGB7 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Isotope Labelled Vedolizumab Biosimilar - Anti-ITGA4_ITGB7 mAb - Research Grade |
|---|---|
| Source | CAS 943609-66-3 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Molecular weight | 147kDa |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | MS |
| Aliases /Synonyms | LDP-02,LDP02,MLN-02,MLN0002,MLN02 |
| Reference | PX-TA1212-SIL |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
Description of Stable Isotope Labelled Vedolizumab Biosimilar - Anti-ITGA4_ITGB7 mAb - Research Grade
General information on Anti-ITGA4_ITGB7(Homo sapiens) (Vedolizumab) Monoclonal Antibody
Vedolizumab is a recombinant humanized monoclonal antibody of isotype IgG1 raised against human lymphocyte ?4?7 integrin, a key mediator of gastrointestinal inflammation. It is used for the treatment of active ulcerative colitis and Crohn’s disease. Vedolizumab can reduce intestinal inflammation by blocking its main target ?4?7 integrin.
Reviews
Il n’y a pas encore d’avis.